/AVXT

AVXT Stock - AVAX Technologies, Inc.

Q: What is the analyst price target for AVXT?

Analyst price target information is not currently available for AVXT.

Q: What is AVXT's market cap?

Market capitalization information is not currently available for AVXT.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AVXT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2003

FY2004

FY2005

FY2006

FY2007

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-55.48

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2007	FY2006	FY2005	FY2004	FY2003
Revenue	$617,384	$734,774	$1.62M	$1.69M	$930,727
Gross Profit	$617,384	$734,774	$1.62M	$1.69M	$930,727
Gross Margin	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income	$6.69M	$5.50M	$3.85M	$3.34M	$3.26M
Net Income	$-6,413,648	$-5,355,500	$-3,703,768	$-3,457,908	$-3,286,100
Net Margin	-1038.8%	-728.9%	-228.1%	-204.5%	-353.1%
EPS	$-0.05	$-0.09	$-0.07	$-0.12	$-0.19

Company Overview

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

Visit Website